Enanta Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Enanta Pharmaceuticals Inc.
iShares Core S&P Small Cap ETF
799,342
4.13%
225
0.15%
09/06/2018
T Rowe Price Health Sciences Fund
494,061
2.54%
494,061
0.35%
06/30/2018
SPDR S&P Biotech ETF
363,204
1.87%
933
0.56%
09/06/2018
Vanguard Total Stock Market Index Fund
360,830
1.86%
0
0%
07/31/2018
iShares Russell 2000 ETF
350,773
1.81%
-186
0.07%
09/06/2018
Fidelity Select Biotechnology Portfolio
284,367
1.47%
0
0.28%
07/31/2018
iShares S&P Small Cap 600 Growth ETF
248,437
1.28%
356
0.31%
09/06/2018
DFA US Small Cap Portfolio
233,098
1.2%
0
0.1%
04/30/2018
iShares Nasdaq Biotechnology ETF
223,311
1.14%
-2,919
0.21%
09/06/2018
Vanguard Extended Market Index Fund
190,531
0.98%
795
0.02%
07/31/2018
| Address |
500 Arsenal Street
Watertown Massachusetts 02472
United States
|
|
Employees
|
- |
| Website |
http://www.enanta.com |
| Updated |
07/08/2019 |
| Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus. The company was founded by Peter O. |
